Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?

The oncologist

article

Carly C. Barron¹  Nidhi Kumar Tyagi²  Muhammad Mustafa Alhussein¹  Som D. Mukherjee²  Peter M. Ellis²  Sukhbinder Dhesy-Thind²  Darryl P. Leong¹ 

[1] Departments of Medicine, McMaster University;Departments of Oncology, McMaster University;Departments of Health Research Methods, McMaster University;The Population Health Research Institute, McMaster University and Hamilton Health Sciences

关键词: Breast cancer;    Trastuzumab;    Cardiotoxicity;    Cardio-oncology;    HER2;   

DOI  :  10.1634/theoncologist.2019-0263

学科分类：地质学

来源: AlphaMed Press Incorporated

【 摘 要 】

Trastuzumab is an effective treatment for HER2-positive breast cancer. Current guidelines recommend withholding trastuzumab in patients experiencing a significant asymptomatic decline in left ventricular function. In this commentary, we discuss the survival benefits afforded by trastuzumab juxtaposed against the risk of trastuzumab-mediated cardiotoxicity. It is not known whether the net benefit of continuing trastuzumab in the setting of mild cardiotoxicity outweighs the associated risks. We describe a potential approach undertaken by our group, and others, and call for a randomized trial.

【 授权许可】

CC BY|CC BY-NC